Member Info for Rocket79

Only FDA cleared technology to retrieve CTC cells. Also i would ask AstraZeneca, Eisai, Recursion, Artios, imaatics, Crescendo, Jubilent Therapeutics why they are using parsortix.

Conclusions

The current study shows the feasibility of a real time HER2 assessment on CTCs enriched from

BC pts.

▪ The developed pipeline was able to count and identify HER2-positive CTCs with higher efficiency than

the gold-standard CellSearch® overall and interestingly, also in the IHC HER2-negative subgroup. This

is a preliminary analysis that should be confirmed in larger cohorts.

▪ HER2 marker is a therapeutic target and an accurate and real-time assessment of the HER2 status

could be used to better guide treatment in a larger cohort of patient with advanced breast cancer with

any detectable HER2 expression that can be effectively treated with antibody-drug conjugates.

From another poser on another BB

Yes great RNS, not least because the research was completely independent. Some points worth noting:-

1) The researchers chose to use Parsortix for this study, but some of each sample was also run through CellSearch for comparison. Parsortix isolataed CTCs in 100% of patient samples whereas CellSearch failed to capture any CTCs in approx. 25% of samples.

2) Taking that a stage further, the workflow using Parsortix identified that 38% of all CTCs captured were HER-2 positive versus only 11% of those captured by CellSearch.

3) 33% of the total CTCs captured from patients previously classified as HER-2 negative were found to be HER-2 positive.

Good stuff.

Whats happening on the 17th December?

Angle have told us exactly where they are with the AstraZeneca contracts:-

1) DDR assay was announced at the end of April with a 6 month development phase to be followed by validation of the assay. Development phase has produced encouraging results and they have moved to the validation phase of testing in patient samples.

2) AR assay for prostate cancer announced May 2024 with estimated completion date of Q1 2025.

I have no idea whether or not AZN will use either or both assays in future clinical trials, but it would be odd to pay a company £700k to develop tests and then not use them. They can only do that as and when appropriate clinical trials are designed, approved and commence.

News could land any time now.

Yes expecting momentum with this joining the Ftse 250 so should break 160p. May take a few attempts then onto 200p.

Expect this to ride up to 160p next resistance. If 160p is broke then this will rise to 200p.

Https://x.com/Parsortix/status/1862095664756248978?t=KQN0CyzQRRfBHZAULNnhDQ&s=19

Angle @ 6th Annual Congress Liquid Biopsy Exhibition Nov 23rd - 25th

Astrazeneca, Thermo Fisher and many others there too:-

https://2024.islb.info/confirmed-partners-exhibitors/

https://icsevents.eventsair.com/ExhibitionPortal/islb2024/exhibitor-portal/floorplan/live

EC have you any info on Artios phase 1 results due by end of 2024. Thanks

2 x catalysts that we know are now due

strazeneca assay

End of April we were told 6 Month development phase. Expecting an update imminently . This could rerate the share price. BUY

"Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response. Assay development will take place in ANGLE's laboratories in Guildford, UK, and follows the Company's development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial £150,000 to ANGLE."

Artios phase 1 results due by end of 2024

The successful development of these DDR assays (high levels of both sensitivity and specificity were achieved) was technically challenging and a significant achievement. Artios will now utilise the two assays in a Phase 1 clinical trial scheduled to begin shortly and expected to complete around the end of 2024. ANGLE anticipates that these assays could be employed in larger, later stage clinical trials for the same compound and potentially in further trials for additional compounds in the customer's pipeline.

End of April we were told 6 Month development phase. Expecting an update imminently . This could rerate the share price. BUY

"Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response. Assay development will take place in ANGLE's laboratories in Guildford, UK, and follows the Company's development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial £150,000 to ANGLE."

Berenberg 70p price target

ANGLE technology sets the gold standard in cancer diagnostics - investment bank

circulating tumour cell (CTC) technology is the 'gold standard' in cancer diagnostics, according to German investment bank Berenberg in a note in which it reiterated its 'buy' recommendation and 70p price target (the shares are 11.28p)

hTtps://www.proactiveinvestors.com/companies/news/1056006/angle-technology-sets-the-gold-standard-in-cancer-diagnostics-investment-bank-1056006.html

Berenberg 70p price target

ANGLE technology sets the gold standard in cancer diagnostics - investment bank

circulating tumour cell (CTC) technology is the 'gold standard' in cancer diagnostics, according to German investment bank Berenberg in a note in which it reiterated its 'buy' recommendation and 70p price target (the shares are 11.28p)

hTtps://www.proactiveinvestors.com/companies/news/1056006/angle-technology-sets-the-gold-standard-in-cancer-diagnostics-investment-bank-1056006.html

Https://www.proactiveinvestors.co.uk/companies/news/1060704/angle-showcases-its-advances-in-cancer-diagnostics-1060704.html

Both tests allow doctors to monitor cancer changes over time with simple blood samples, helping them adjust treatments as the disease evolves.

Excellent work. Everything on track. This alone could transform Angle. Major partner in Bioview . No brainer here with pleny of other projects in pipeline, not to mention AstraZeneca.

ANGLE technology sets the gold standard in cancer diagnostics - investment bank

circulating tumour cell (CTC) technology is the 'gold standard' in cancer diagnostics, according to German investment bank Berenberg in a note in which it reiterated its 'buy' recommendation and 70p price target (the shares are 11.28p)

https://www.proactiveinvestors.com/companies/news/1056006/angle-technology-sets-the-gold-standard-in-cancer-diagnostics-investment-bank-1056006.html

Some major buying now. Smart money buying up the shares being sold for a small profit. Long term holders will be rewarded.

Excellent numbers from AZ esp from the drugs we are currently targeting.

Tagrisso up a further 11% 9 month revenue of $5bn. Looking at other cancer areas for the drug

Enhertu (Breast cancer) up 57% to 9 months almost $1,5bn

This ended up 30p± when news dropped Jan 24. Todays news confirms this. Im expecting a steady rise from here but it wont be smooth sailing. No reason why this should not be over 30p on this news. Once news sinks in this will rise. Dont miss the boat. Good luck all